10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 101–200 of 1,169
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationDiabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
“Temporal progression of DPDs The time of onset of panvascular complications in patients with diabetes is closely associated with patient age,(294) race,(295) genetic background,(296) DM staging,(297) treatment regimen,(298,299) and level of glycemic control.(300,301) The natural course of DPDs is not completely clear,…”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
Nutrition therapy recommendations for the management of adults with diabetes
Evert, A. B., Boucher, J. L., Cypress, M., Dunbar, S. A., Franz, M. J., Mayer-Davis, E. J., Neumiller, J. J., Nwankwo, R., Verdi, C. L., Urbanski, P., et al. (2014) · Diabetes Care · doi:10.2337/dc14-s120 · Cited by 766
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Long-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (40).”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
“This is exemplified by the treatment-limiting side effects of many available antidiabetic agents, particularly in patients with a longer duration of disease (2-5).”
BackgroundSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Diabetes Care · doi:10.2337/dc11-9998 · Cited by 718
“Long-term follow-up of the United Kingdom Prospective Diabetes Study (UKPDS) population supported a benefit of intensive therapy on macrovascular disease (49), but three other recent trials failed to demonstrate a significant difference in macrovascular disease outcomes between very intensive treatment strategies, whi…”
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
“in myocardial infarction and mortality in the former intensive treatment pat ient cohort, unlike the results of other studies of type 2 diabetes, including the VADT, involving older individuals with longer duration of diabetes and a greater incidence of preexisting CVD and/or CVD risk factors at baseline (7,30,31,32).”
ResultStandards of medical care for type 2 diabetes in China 2019
Jia, W., Weng, J., Zhu, D., Ji, L., Lu, J., Zhou, Z., Zou, D., Guo, L., Ji, Q., Chen, L., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3158 · Cited by 700
“Good control of blood glucose, blood pressure, and lipids may prevent or delay the progression of diabetic retinopathy.(21,116,117)”
BackgroundAnti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704
“previous studies demonstrated a substantial beneficial effect of metformin therapy on cardiovascular outcomes.(2,44,45) Together,”
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
“The impact of glucose control on cardiovascular complications remains uncertain; a more modest benefit is likely to be present, but probably emerges only after many years of improved control [5].”
BackgroundSelf-citationSodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.007 · Cited by 691
Li, G., Zhang, P., Wang, J., An, Y., Gong, Q., Gregg, E. W., Yang, W., Zhang, B., Shuai, Y., Hong, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70057-9 · Cited by 684
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
“diet) on the relative benefits of metformin and sulfonylureas for the spectrum of long-term outcomes important in diabetes (32).”
BackgroundEzekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
“pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (22).”
BackgroundHall, V., Thomsen, R. W., Henriksen, O., & Lohse, N. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-564 · Cited by 624
“Assessing the public health importance of diabetes demands an appreciation of the impact of diabetes on other diseases and population mortality, and in particular the benefits of well-controlled diabetes for averting costly cardiovascular and microvascular complications [7,94].”
BackgroundUpdate on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“Sulfonylureas are the most cost-effective glucose-lowering agents, have been on the market for a long time [37] , and are widely utilized because of their long term efficacy and safety history, low cost and extensive clinical trial data demonstrating good glucose-lowering efficacy [76,77] .”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Chamberlain, J. J., Rhinehart, A. S., Shaefer, C. F., & Neuman, A. (2016) · Annals of Internal Medicine · doi:10.7326/m15-3016 · Cited by 631
“It is inexpensive, has a longestablished evidence base for efficacy and safety, and may reduce risk for cardiovascular events and death (25, 26).”
BackgroundEffect of diet on type 2 diabetes mellitus: a review
Khazrai, Y. M., Defeudis, G., & Pozzilli, P. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2515 · Cited by 626
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Metformin: clinical use in type 2 diabetes
Sanchez-Rangel, E., & Inzucchi, S. E. (2017) · Diabetologia · doi:10.1007/s00125-017-4336-x · Cited by 595
“In the 10-year follow-up of the UKPDS cohort, these cardiovascular benefits also appeared to be sustained [27].”
BackgroundFollow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626
Self-citationHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
“These findings may have future clinical implications as past studies show worse glycemic control in younger participants with type 2 diabetes [3, 4] and this new sensor-based technology may be helpful for these participants.”
BackgroundClinical Inertia in People With Type 2 Diabetes
Khunti, K., Wolden, M. L., Thorsted, B. L., Andersen, M., & Davies, M. J. (2013) · Diabetes Care · doi:10.2337/dc13-0331 · Cited by 613
Fuster, V., & Kelly, B. B. (2010) · Cited by 682
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
“To make well-informed choices among the options for achieving glucose control, clinicians and patients need comprehensive information about the effectiveness and the safety of therapies, with attention to patient-relevant outcomes (4, 9, 10).”
Background(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Global estimates of undiagnosed diabetes in adults
Beagley, J., Guariguata, L., Weil, C., & Motala, A. A. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.001 · Cited by 586
“[12] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW.”
BackgroundDiabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Trends in prevalence of diabetes in Asian countries
Ramachandran, A. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i6.110 · Cited by 561
Nelson, G., Altman, A. D., Nick, A., Meyer, L. A., Ramirez, P. T., Achtari, C., Antrobus, J., Huang, J., Scott, M., Wijk, L., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.019 · Cited by 562
Laiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
“10 and 25 additional years, respectively (1,4).”
BackgroundEmerging Targets in Type 2 Diabetes and Diabetic Complications
Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 525
Yahagi, K., Kolodgie, F. D., Lutter, C., Mori, H., Romero, M. E., Finn, A. V., & Virmani, R. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.306256 · Cited by 573
Nordanstig, J., Behrendt, C.-A., Baumgartner, I., Belch, J., Bäck, M., Fitridge, R., Hinchliffe, R., Lejay, A., Mills, J. L., Rother, U., et al. (2024) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.08.067 · Cited by 515
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
“002) [73].”
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s006 · Cited by 486
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
Kimura, K., Kimura, T., Ishihara, M., Nakagawa, Y., Nakao, K., Miyauchi, K., Sakamoto, T., Tsujita, K., Hagiwara, N., Miyazaki, S., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0133 · Cited by 565
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Brethauer, S. A., Aminian, A., Romero-Talamás, H., Batayyah, E., Mackey, J., Kennedy, L., Kashyap, S. R., Kirwan, J. P., Rogula, T., Kroh, M., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182a5034b · Cited by 552
“n/total (%) 6/212 (3) 45/168 (27) 53/187 (28) <0.”
Diabetes in Older Adults: A Consensus Report
Sue Kirkman, M., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12035 · Cited by 548
Impact of diabetes on cardiovascular disease: an update
Matheus, A. S. D. M., Tannus, L. R. M., Cobas, R. A., Palma, C. C. S., Negrato, C. A., & Gomes, M. D. B. (2013) · International Journal of Hypertension · doi:10.1155/2013/653789 · Cited by 547
“In recent decades, several clinical trials have investigated the effect of intensive treatment of hyperglycemia on cardiovascular risk reduction, in both T2D [22–25] and T1D [26] presenting conflicting results.”
BackgroundJapanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Pop-Busui, R., Evans, G. W., Gerstein, H. C., Fonseca, V., Fleg, J. L., Hoogwerf, B. J., Genuth, S., Grimm, R. H., Corson, M. A., Prineas, R., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0125 · Cited by 540
“Furthermore, the long-term follow-up of the UKPDS cohort reported risk reductions for myocardial infarction and death from any cause associated with intensive glucose control (22).”
BackgroundIncreased mortality of patients with diabetes reporting severe hypoglycemia
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2012) · Diabetes Care · doi:10.2337/dc11-2054 · Cited by 539
Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., & El-Osta, A. (2009) · Diabetes · doi:10.2337/db08-1666 · Cited by 534
“More recently, the long-term outcomes, in particular cardiovascular outcomes, from the UKPDS suggest that the period of intensive glycemic control that occurred more than a decade ago and initially did not demonstrate statistically significant reductions in macrovascular disease, now shows clear benefits on a range of…”
BackgroundIto, F., Sono, Y., & Ito, T. (2019) · Antioxidants · doi:10.3390/antiox8030072 · Cited by 535
“In addition, the UK Prospective Diabetes Study (UKPDS) demonstrated that intensive glycemic control reduced the development of cardiovascular disease (CVD) as well as diabetic microangiopathy during long-term follow up of patients with type 2 diabetes (T2DM) [65].”
BackgroundDiabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis
Gorst, C., Kwok, C. S., Aslam, S., Buchan, I., Kontopantelis, E., Myint, P. K., Heatlie, G., Loke, Y., Rutter, M. K., & Mamas, M. A. (2015) · Diabetes Care · doi:10.2337/dc15-1188 · Cited by 530
Gæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4065-6 · Cited by 528
“Long-term beneficial effects of glucose-lowering treatment in reducing microvascular complications have been demonstrated beyond the duration of a clinical trial in both type 1 and type 2 diabetes [20, 25, 26].”
BackgroundAmiel, S. A., Aschner, P., Childs, B., Cryer, P. E., de Galan, B. E., Frier, B. M., Gonder-Frederick, L., Heller, S. R., Jones, T., Khunti, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30315-2 · Cited by 526
for the ADVANCE Collaborative group, Zoungas, S., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., Marre, M., Patel, A., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3369-7 · Cited by 497
Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection
Long, A. N., & Dagogo‐Jack, S. (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00434.x · Cited by 491
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Diabetes Care · doi:10.2337/dci15-0012 · Cited by 492
“01) reduction in MI became significant only after 10 years of observational follow-up of theUKPDS population, despite the convergence of mean A1c soon after the randomized component of the study ended (135).”
Huang, E. S., Laiteerapong, N., Liu, J. Y., John, P. M., Moffet, H. H., & Karter, A. J. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12956 · Cited by 501
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
DeFronzo, R. A., Davidson, J. A., & Del Prato, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01511.x · Cited by 493
“As showed by the recent 20-year follow-up of the United Kingdom Prospective Diabetes Study, improved control of blood glucose in newly diagnosed patients significantly decreases the long-term risk of both microvascular and macrovascular complications [22].”
BackgroundAhrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
Hayes, A. J., Leal, J., Gray, A. M., Holman, R. R., & Clarke, P. M. (2013) · Diabetologia · doi:10.1007/s00125-013-2940-y · Cited by 495
Self-citationYeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Adherence to diabetes medication: a systematic review
Krass, I., Schieback, P., & Dhippayom, T. (2015) · Diabetic Medicine · doi:10.1111/dme.12651 · Cited by 453
Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus
Katakami, N. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17014 · Cited by 472
Nelson, G., Altman, A. D., Nick, A., Meyer, L. A., Ramirez, P. T., Achtari, C., Antrobus, J., Huang, J., Scott, M., Wijk, L., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.015 · Cited by 458
US Preventive Services Task Force, Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Krist, A. H., et al. (2021) · JAMA · doi:10.1001/jama.2021.12531 · Cited by 480
Khunti, K., Gray, L. J., Skinner, T., Carey, M. E., Realf, K., Dallosso, H., Fisher, H., Campbell, M., Heller, S., & Davies, M. J. (2012) · BMJ · doi:10.1136/bmj.e2333 · Cited by 465
Oxidative Stress in Diabetic Nephropathy
Kashihara, N., Haruna, Y., K. Kondeti, V., & S. Kanwar, Y. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710793348581 · Cited by 464
“Since the microvascular injury is usually related to the chronic sustained hyperglycemia, therefore, to control hyperglycemia would be first line of effective measure to seek amelioration from the diabetic complications as concluded from the two large clinical trials, i.e., the Diabetic Control and Complications Trial…”
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.008 · Cited by 471
8. Pharmacologic Approaches to Glycemic Treatment
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s011 · Cited by 458
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (22).”
BackgroundCardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
“Moreover, a continued benefit of reductions in microvascular risk, myocardial infarction and death over 10 years after metformin therapy in that trial were reported [46].”
BackgroundGriffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462
Perrone, A., Giovino, A., Benny, J., & Martinelli, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3818196 · Cited by 459
“The induction of ROS in mitochondrial structures has been associated with the induction of pathways of hyperglycemic disease such as the upregulation of polyol pathways, induction of protein kinase C signaling, and enhanced production of AGEs [156].”
BackgroundAge-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk
Chia, C. W., Egan, J. M., & Ferrucci, L. (2018) · Circulation Research · doi:10.1161/circresaha.118.312806 · Cited by 454
“And, of great interest, after mining the data from the UKPDS trial (United Kingdom Prospective Diabetes Study), early lowering of blood glucose, by any means, seemed tied into lower CVD at later times, in what is termed the legacy effect.(196) However, further follow-up for 2.”
BackgroundMetformin and inflammation: its potential Beyond glucose-lowering effect
Saisho, Y. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316124019 · Cited by 450
Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0167-x · Cited by 417
“Reassuringly, prior intensive therapy was associated with long-term reductions in CHD during the observational follow-up studies of both the DCCT and UKPDS [17, 18], although the Action to Control Cardiovascular Risk in Diabetes (ACCORD; ClinicalTrials.gov identifier: NCT00000620) study group reported previously unrec…”
BackgroundInfluential6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality
Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015) · JAMA · doi:10.1001/jama.2014.16107 · Cited by 437
Atherton, J. J., Sindone, A., De Pasquale, C. G., Driscoll, A., MacDonald, P. S., Hopper, I., Kistler, P. M., Briffa, T., Wong, J., Abhayaratna, W., et al. (2018) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2018.06.1042 · Cited by 431
“The effect of glucose lowering on the risk of cardiovascular events and heart failure in patients with diabetes mellitus has been less clear; however, longer term follow-up over 10 years suggests this will decrease the risk of cardiovascular events [45].”
BackgroundDiabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
Beckman, J. A., Paneni, F., Cosentino, F., & Creager, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht142 · Cited by 434
“tion in death from any cause, both significantly more than that in the patients in the sulfonylurea arm.(76) The value of metformin has been supported in other studies as well.”
Result
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.